Introducing Gyros Gyrolab and ELISA Technologies
Radix Continues to Implement New Technologies
The Luminex xMAP technology is a mature technology platform that provides users with the ability to assess the qualitative or quantitative expression of multiple biomarkers, nucleic acid sequences, immune responses, and a multitude of other biomolecular interactions simultaneously. In addition to generating more information per sample through multiplexing, the integration of our AssayCheX™ Process Controls into every xMAP analyzed sample increases the integrity of every data point generated. AssayCheX Process Controls ensure that the assay reagents are functional and that the assay process was performed correctly and accurately for every sample that is analyzed. Although xMAP technology is an extremely versatile assay technology, we realize that certain sample analyses have requirements that are better suited to alternate technologies. Therefore, to complement and expand our assay capabilities beyond xMAP, we have implemented both Gyros Gyrolab and ELISA technologies into our bioanalytical sample testing services.
The Gyrolab System
To complement the vast multiplexing capabilities of the Luminex xMAP technology, we have integrated the Gyrolab platform from Gyros into our palette of technology offerings. The Gyrolab system outperforms many immunoassay platforms with its small sub-microliter sample size requirements, extended dynamic range, parallel processing of samples, assay turnaround time, and automated assay processing. These core capabilities of the Gyrolab system well positions the technology for use in preclinical animal studies by offering sample size requirements that permit repetitive sampling from individual animals which saves animal costs and enhances data quality. This allows longitudinal studies to be performed from the same animal instead of surrogate animals. Automated assay processing and parallel sample processing enhance data integrity since human pipetting errors are removed and there are no sample incubation time differences.
To meet straightforward, single analyte needs of many customers, Radix has implemented ELISA-based immunoassays. ELISA remains the industry standard based on their acceptance by regulatory agencies, performance, ease of use, low consumable cost, and low capital equipment costs. The limitations to ELISA-based immunoassays include their relatively high sample volume requirements, slower binding kinetics of analyte to the capture phase, single analyte measurement capabilities, and batch to batch variation in coating plates with capture antibody. To address some of these limitations, Radix will implement a slight variation on the standard plate-based ELISA by utilizing paramagnetic microspheres as the solid phase for capture reagent coating for their in-house developed assays.
To place an order or for additional information, please email email@example.com.